Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Induject, specifically Induject-250, is an injectable oil-based solution containing a blend of four testosterone esters: testosterone propionate, testosterone phenylpropionate, testosterone isocaproate, and testosterone decanoate. Developed and manufactured by Alpha-Pharma Healthcare, this formulation is designed to mimic the pharmacokinetic profile of the well-known Sustanon 250. The combination of short-, medium-, and long-acting esters allows for both a rapid onset of action and a prolonged therapeutic effect, maintaining stable testosterone levels over an extended period. Induject is primarily indicated for testosterone replacement therapy in males with primary or secondary hypogonadism. Its mechanism of action involves the activation of the androgen receptor, which regulates gene expression to promote the development of male sexual characteristics, increase muscle mass, and maintain bone density.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on testosterone propionate + testosterone phenylpropionate + testosterone isocaproate + testosterone decanoate.